comprehensive -WSS

comprehensive

author：explore 2025-09-28 02:28:12 - browse：95

Joaquin Duato -- health policy coverage from STAT — Johnson & Johnson CEO Joaquin Duato MICHAEL BUHOLZER/AFP via Getty Images

WASHINGTON — Merck CEO Robert Davis and Johnson & Johnson CEO Joaquin Duato have agreed to voluntarily testify before the Senate health committee, avoiding a threatened subpoena, the committee announced Friday.

The decision by the executives came after a public pressure campaign by Sanders to get the two executives and Bristol Myers Squibb CEO Chris Boerner to testify about why prices for their drugs are higher in the United States than in other countries. Sanders had scheduled a vote to subpoena the Merck and Johnson & Johnson CEOs on Jan. 31, but canceled it on Friday.

“The use of a subpoena was clearly a last resort and I’m delighted that these CEOs will be coming into our committee voluntarily,” Sanders said in a written statement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： YouTube cracks down on misinformation on cancer treatment

hotspot

WSS

STAT Virtual Event: How to Increase Diversity in Clinical Trials

FDA seeks to regulate lab

Researchers use wearables data and AI to predict preterm birth risk

Listen: Who gets the credit for GLP

How one patient went off dialysis — and others can too

Biogen’s boardroom scandal saddles CEO with first crisis

entertainment

comprehensive

knowledge

Peter Hotez and the public health issue of online harassment

Bird flu researchers hone in on Finland’s mink farms

Sports medicine is finally prioritizing gender equality

Patients, digital health players weigh in on FTC's data privacy plan

Malaria cases in Florida and Texas: Here’s what you need to know

FDA advisers vote against ALS treatment from BrainStorm

Wildfire smoke exposes gaps in outdoor worker protections

Sudafed saga points to U.S. issues with evaluating older drugs

Heart attack and stroke risk calculators need revising

FDA advisers vote against ALS treatment from BrainStorm

focus

Timeline: How the deadly wildfires took over Maui day by day

Treatments for cramps don't cut it. Why aren't there better options?

Dozens dead from Maui wildfires: What we know about the victims

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Would Medicare drug price negotiations stall in a shutdown?

Data show record exodus of life scientists from academia

focus

focus

hotspot

focus